Table 4.
Drug-eluting stents (DES) with biodegradable polymers as coating materials [56].
| Trade Name | Stent Platform | Polymer System | Drug | Drug Release (Days) | Manufacturer | Approval |
|---|---|---|---|---|---|---|
| SynergyTM | Pt-Cr | PLGA | Everolimus | (60) 50% (90) 100% |
Boston Scientific (Marlborough, MA) | FDA, CE |
| AxxessTM | Nitinol | PLA | Biolimus A9 | (30) 45% | Biosensors (Irvine, CA) | CE |
| BioMatrix FlexTM | SS | PLA | Biolimus A9 | (30) 45% | Biosensors (Irvine, CA) | CE |
| Nobori® | SS | PLA | Biolimus A9 | (30) 45% | Terumo (Somerset, NJ) | CE |
| Supralimus® | SS | PLLA-PLGA-PCL-PVP | Sirolimus | (48) 100% | SMT (Mumbai, India) | CE |
| Orsiro | Co-Cr | PLLA + silicon carbide | Sirolimus | (30) 50% (90) 80% |
Biotronik (Poznań, Poland) | CE |
| BioMimeTM | Co-Cr | PLLA + PLGA PLLA + PLGA | Sirolimus | (30) 100% | Meril (Gujarat, India) | CE |
| Inspiron® | Co-Cr | PLLA, PDLLGA PLLA, PDLLGA | Sirolimus | (10) 60% (45) 100% |
SciTech Medical (Aparecida de Goiânia, Brasil) | Phase IV NCT01856088 |
| Firehawk® | Co-Cr | PDLLA | Sirolimus | (90) 90% | MicroPort Medica (Shanghai, China) | CE |
| DESyne® BD | Co-Cr | PLA | Novolimus M | (90) 90% | Elixir® (Milpitas, CA) | CE |
| MiStent SES® | Co-Cr | PLGA | Sirolimus | (270) 100% | Micell Technologies (Durham, SC) | CE |
| Tivoli® | Co-Cr | PLGA | Sirolimus | (7) 50% (28) 80% |
Essen Technology (Beijing, China) | Phase III NCT02448524 |
Pt-Cr: platinum chromium, SS: stainless steel, and Co-Cr: cobalt-chromium.